Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 6,882 matching trials from the live ClinicalTrials.gov search.
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Conditions
Pulmonary Embolism
Interventions
Denali inferior vena cava filter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

NCT04971109
Conditions
Smallpox
Interventions
TPOXX, TPOXX Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
9
States / cities
Miami, Florida • Orlando, Florida • Omaha, Nebraska + 5 more
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more
Conditions
Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Brexucabtagene Autoleucel
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
U.S. locations
50
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-916, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Tucson, Arizona • Irvine, California • San Diego, California + 23 more
Completed Not applicable Interventional Accepts healthy volunteers

Improving Mechanics and Confidence in the Hip Hinge

NCT06871098
Conditions
Hip Hinge, Hip and Knee Movement
Interventions
Hip Hinge Instruction
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Recruiting No phase listed Observational

Patient Retrospective Outcomes (PRO)

NCT01550575
Conditions
Chronic Pain
Interventions
Non Boston Scientific Systems, Boston Scientific Systems
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
87
States / cities
Lake Havasu City, Arizona • Phoenix, Arizona • Bakersfield, California + 76 more
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more
Conditions
Chronic Hepatitis C Infection
Interventions
Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV)
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Rialto, California • San Francisco, California • Aurora, Colorado + 7 more
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Conditions
Cytomegalovirus
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
9 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
44
States / cities
La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more
Recruiting No phase listed Observational

Natural History of Wilson Disease

NCT03334292
Conditions
Wilson Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
4
States / cities
New Haven, Connecticut • Orlando, Florida • Houston, Texas + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

NCT05934292
Conditions
Hypercholesterolaemia
Interventions
Enlicitide Decanoate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Hallandale, Florida • Miami, Florida • Orlando, Florida + 1 more
Completed No phase listed Observational Results available

Flexiva Pulse Registry

NCT05027971
Conditions
Urinary Calculi, Benign Prostatic Hyperplasia
Interventions
Flexiva Pulse High Power Single-Use Laser Fibers
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Orlando, Florida + 1 more
Conditions
Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
Interventions
DCC-3084
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Conditions
Social Anxiety Disorder
Interventions
Cannabidiol oral solution, Placebo
Drug
Lead sponsor
EmpowerPharm Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Encino, California • Lemon Grove, California • Los Alamitos, California + 14 more
Conditions
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
Interventions
Cabozantinib, Cabozantinib S-malate, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 30 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
142
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Completed Phase 3 Interventional Results available

A Moderate to Severe Rheumatoid Arthritis Study

NCT01721044
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Conditions
Solid Tumors
Interventions
BI 1831169, anti-PD-1 antibody
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 13 more
Conditions
HIV
Interventions
CAB ULA, RPV ULA, CAB LA, RPV LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 36 more
Conditions
Renal Transplantation
Interventions
Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more